[3 days and 2 boards Laimei Pharmaceutical: Nanocarbon-iron combined radiotherapy is still in phase II clinical trials] On October 14th, Laimei Pharmaceutical (300006.SZ) issued an announcement of abnormal stock trading fluctuations. The company is concerned that the market and media have recently paid attention to the clinical trials of the company’s nanocarbon-iron suspension injection (CNSI-Fe) (referred to as nanocarbon-iron). This matter is mainly due to the company's holding subsidiary Ingrui Medicine recently publishing academic papers on the Phase I clinical trial of its independently developed nanocarbon iron in relevant academic journals, as well as the interpretation of clinical trial results or individual case results disclosed by relevant partner hospitals. As of now, nanocarbon iron combined with radiotherapy is still in the phase II clinical trial stage. Subsequently, the results of the phase II clinical trial of combined radiotherapy must be used to advance the application for breakthrough therapy designation, or conduct phase III clinical trials, apply for drug marketing authorization (NDA) and other core links. There are major uncertainties in the above-mentioned core links, and there are risks such as the results of phase II clinical trials not meeting expectations, the inability to apply for or be approved for breakthrough therapy designation, the inability to conduct or complete phase III clinical trials, the inability to submit or approve NDA, and the delay in review and approval progress.